Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
By H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet and 24 more. Blood, 2007
933 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/8f795ad0bb9b4c25f97dfaf32a8eb2d409620032
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. (2009, background): “Several disease- and host-related factors have been shown to influence the disease course in myeloma, but there is increasing appreciation that the primary driver is the genetic heterogeneity present in the disease.(32-36) Several genetic risk stratification systems using different genetic abnormali”
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010, neutral): “Median age, y (range) 58 (22-86) 59 (22-86)”